Coronary Stents Market to Reach USD 38.5 Billion by 2033 | Abbott, Medtronic, Boston Scientific Lead - Fact.MR

The global coronary stents market size is valued at US$ 13.7 Billion in 2023, and is projected to reach US$ 38.5 Billion by 2033, at a growing Compound Annual Growth Rate (CAGR) of 10.8% during the forecast period from 2023 to 2033.This significant expansion is driven by the rising prevalence of cardiovascular diseases, an aging global population, and advancements in minimally invasive procedures like coronary stenting. The market is benefiting from increased demand for drug-eluting stents (DES), which dominate with an 80% market share, and innovations such as bio-absorbable stents that cater to the growing need for safer and more effective treatments. North America leads with a 30% market share, while regions like Asia-Pacific, particularly China, are emerging as high-growth markets due to increasing healthcare investments and lifestyle-related health issues. However, challenges such as stringent regulatory approvals and high treatment costs may pose hurdles to market growth. The market's trajectory reflects a combination of technological innovation, rising healthcare needs, and strategic industry efforts to address cardiovascular challenges globally.

For More Insights, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=7275

Coronary Stents Market Technology Development:

Technological advancements are at the forefront of the coronary stents market, revolutionizing treatment outcomes and patient recovery. The shift toward drug-eluting stents (DES), which account for 80% of the market in 2023, is driven by their ability to reduce restenosis rates compared to bare metal stents (BMS). DES are coated with medications that prevent scar tissue formation, improving long-term outcomes for patients undergoing percutaneous coronary intervention (PCI). Recent innovations include the development of bio-absorbable stents, which dissolve over time, reducing long-term complications like stent thrombosis. For instance, Biotronik's Orsiro Mission, a bioabsorbable polymer DES, received FDA approval in 2021, highlighting the focus on safer, more biocompatible materials.

Additionally, advancements in stent design, such as improved flexibility and deliverability, have enhanced procedural success rates. Companies like Medtronic launched the Onyx Frontier DES in August 2022, which offers superior deliverability for complex PCI cases. The integration of digital health technologies, such as real-time imaging and AI-assisted stent placement, is further improving precision during procedures. These innovations align with the global push for minimally invasive treatments, reducing recovery times and the need for invasive surgeries like coronary artery bypass grafting (CABG). As manufacturers invest in R&D to develop next-generation stents, the market is poised to meet evolving clinical and patient demands while adhering to stringent safety standards.

Coronary Stents Market Demand and Impact Analysis:

The demand for coronary stents is propelled by the global rise in cardiovascular diseases (CVDs), which remain a leading cause of mortality. According to the National Center for Health Statistics, coronary artery disease (CAD) accounts for 1 in 4 deaths in the United States, with 785,000 first heart attacks and 470,000 recurrent myocardial infarctions annually. The growing prevalence of risk factors like hypertension, obesity, and sedentary lifestyles, particularly in emerging economies, is driving demand for stents. The geriatric population, projected to reach 2 billion by 2050, further amplifies the need for coronary interventions, as age-related cardiovascular issues become more prevalent.

The shift toward outpatient coronary stenting has significantly boosted market growth by reducing hospitalization times and costs. Bio-absorbable stents are gaining traction due to their ability to minimize long-term complications, while drug-eluting stents remain the preferred choice for their efficacy in preventing restenosis. However, challenges such as high treatment costs, product recalls due to issues like stent deformation, and stringent regulatory approvals could restrain growth. The availability of alternative treatments, such as medication-based therapies or bypass surgery, also poses competition. Despite these hurdles, rising healthcare expenditure and increasing awareness of minimally invasive procedures are creating opportunities for market expansion, particularly in regions with improving healthcare infrastructure.

Coronary Stents Market Analysis by Top Investment Segments:

The coronary stents market is segmented by product type (bare metal stents, drug-eluting stents, and bio-absorbable stents) and region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa). Among product types, drug-eluting stents (DES) are the most lucrative segment, holding an 80% market share in 2023 due to their superior clinical outcomes and widespread use in PCI and myocardial infarction treatments. The DES segment is expected to grow at a high CAGR, driven by ongoing innovations and increasing adoption in specialty clinics. Bio-absorbable stents are emerging as a high-potential investment area, as they address concerns about long-term complications associated with permanent stents, appealing to both patients and healthcare providers.

Regionally, North America dominates with a 30% market share, fueled by high CVD prevalence, advanced healthcare infrastructure, and significant R&D investments. The United States, in particular, benefits from the presence of key players like Abbott Laboratories and Boston Scientific, alongside a high volume of stent implantation procedures. Asia-Pacific, led by China and India, is the fastest-growing region due to rising healthcare spending, increasing adoption of sedentary lifestyles, and a growing aging population. China's market is forecasted to exhibit a higher CAGR than other Asian countries, driven by ongoing clinical trials and government support for healthcare advancements. These segments offer significant investment opportunities for companies focusing on innovation and geographic expansion.

Coronary Stents Market Across Top Countries:

1.China: The market is propelled by rapid urbanization, poor dietary habits, and an expanding geriatric population. Increasing healthcare investments and clinical trials for novel stents are boosting growth, with China expected to exhibit the highest CAGR in Asia-Pacific.

2.United States: Valued at a significant portion of the global market, the U.S. benefits from high CVD prevalence (1 in 4 deaths) and robust R&D. Specialty clinics and innovations like Medtronic's Onyx Frontier DES drive demand.

3.India: Rising cardiovascular cases and improving healthcare infrastructure make India a high-growth market. Government initiatives to enhance medical access further support stent adoption.

4.Germany: As a key European market, Germany sees growth due to increasing R&D investments and a high incidence of CVDs. Companies like Biotronik are leading with innovative stent designs.

5.Japan: With a strong focus on advanced medical technologies, Japan is a significant market, driven by its aging population and high healthcare standards. Terumo Corporation is a key player here.

Leading Coronary Stents Companies and Their Industry Share:

The coronary stents market is highly competitive, with leading players including Abbott Laboratories, Boston Scientific Corporation, Medtronic Inc., Terumo Corporation, B. Braun Melsungen AG, C. R. Bard Inc., Cook Medical Inc., Biotronik SE & Co. KG, and MicroPort Scientific Corporation. These companies dominate through extensive R&D, strategic acquisitions, and global distribution networks. Abbott and Medtronic lead due to their innovative DES portfolios, with products like Abbott's Xience and Medtronic's Onyx Frontier setting industry standards. Boston Scientific maintains a strong presence with its advanced stent designs, while Terumo leverages its expertise in Japan and Europe, as seen with the Ultimaster NagomiTM stent study launched in April 2023.

Recent strategic moves include Olympus' acquisition of Taewoong Medical in February 2023 for USD 370 million, expanding its stent portfolio, and Cardiovascular Systems Inc.'s partnership with Chansu Vascular Technologies in February 2021 to develop advanced coronary balloons. These initiatives highlight the industry's focus on innovation and market expansion. While global players dominate, regional manufacturers in emerging markets like China and India contribute to market fragmentation, offering cost-effective solutions tailored to local needs.

Coronary Stents Market Historic and Future Pathway Analysis:

Historically, the coronary stents market has grown steadily, driven by the rising incidence of CVDs and advancements in stent technology. From 2018 to 2023, the market expanded from approximately USD 10 billion to USD 13.7 billion, reflecting a strong CAGR driven by the adoption of DES and minimally invasive procedures. The shift from bare metal stents to DES and bio-absorbable stents has been a key trend, spurred by clinical evidence of better outcomes and patient safety.

Looking forward, the market is expected to grow at a 10.8% CAGR through 2033, reaching USD 38.5 billion. This growth will be fueled by increasing CVD prevalence, an aging population, and innovations in bio-absorbable and next-generation DES. Emerging markets, particularly in Asia-Pacific, will drive demand due to rising healthcare investments and lifestyle-related health issues. Challenges like product recalls, high costs, and regulatory hurdles will require companies to invest in R&D and compliance to maintain competitiveness. Strategic partnerships, mergers, and acquisitions will also shape the market, ensuring alignment with global healthcare trends and patient needs.

Buy the Full Report Now: https://www.factmr.com/checkout/7275

Coronary Stents Industry News:

1.In April 2023, Terumo Europe N.V. launched a clinical study for its Ultimaster NagomiTM sirolimus-eluting stent, approved with a CE mark in November 2022, targeting complex PCI patients.

2.In February 2023, Olympus acquired Taewoong Medical for USD 370 million, enhancing its stent offerings.

3.In August 2022, Medtronic introduced the Onyx Frontier DES, emphasizing improved deliverability and flexibility.

Explore More Related Studies Published by Fact.MR Research:

Normal Balloon Catheter Market-https://www.factmr.com/report/147/normal-balloon-catheter-market
Lewy Body Dementia Treatment Market-https://www.factmr.com/report/1154/lewy-body-dementia-treatment-market
Vestibular Testing Systems Market-https://www.factmr.com/report/1313/vestibular-testing-market
Coronary Stents Market-https://www.factmr.com/report/coronary-stents-market
Durable Medical Equipment Market-https://www.factmr.com/report/durable-medical-equipment-market
Q-TOF Mass Spectrometry Market-https://www.factmr.com/report/q-tof-mass-spectrometry-market
Nursing Breast Pads Market-https://www.factmr.com/report/nursing-breast-pads-market
Medical Pendant Market-https://www.factmr.com/report/medical-pendant-market
Immunoprecipitation Market-https://www.factmr.com/report/immunoprecipitation-market

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com

About Fact.MR:

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.